Actinium Pharmaceuticals
ATNM
30 hedge funds and large institutions have $5.02M invested in Actinium Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 30 → 30 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.09% less ownership
Funds ownership: 0.44% → 0.34% (-0.09%)
40% less capital invested
Capital invested by funds: $8.43M → $5.02M (-$3.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$119K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$101K |
| 3 |
SCM
Sio Capital Management
New York
|
+$51.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$22.2K |
| 5 |
Barclays
London,
United Kingdom
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$536K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$142K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$97.7K |
| 4 |
Morgan Stanley
New York
|
-$43.6K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$15.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | -$2.1K | -67 | -31% |
|
|
CLOS
27
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $4K | – | – | – |
|
28
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $3K | +$3.97K | +127 | New |
|
30
Creative Planning
Overland Park,
Kansas
| $1K | +$845 | +27 | New |
|
|
SPC
31
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$14K | -333 | Closed |
|
|
AIM
32
Acrospire Investment Management
Chicago,
Illinois
| – | -$8K | -187 | Closed |
|
33
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | -21 | Closed |
|
ATNM Hedge Fund Activity: Q4 2016 in Review
30 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2016, worth a combined $5.02M — down 40% from $8.43M a quarter earlier.
Fund positioning in ATNM was balanced in Q4 2016: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $119K. The largest seller was Sabby Management, cutting an estimated $536K.
- 30 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $5.02M of Actinium Pharmaceuticals stock for Q4 2016, down 40% quarter-over-quarter.
- 4 funds opened new Actinium Pharmaceuticals positions in Q4 2016 and 4 closed out, a net change of 0 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2016 was Renaissance Technologies, an estimated $119K added.
- The largest Actinium Pharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $536K sold.
Based on aggregated 13F filings for Q4 2016.